NAD(P)(+) - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	NAD(P)(+)	go back to main search page
Accession:	CHEBI:13390	browse the term
Definition:	A coenzyme that may be NAD(+) or NADP(+).

show annotations for term's descendants Sort by:
Rat (190) Mouse (183) Human (191) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (190)

NAD(+)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminocarboxymuconate semialdehyde decarboxylase

increases abundance

ACMSD protein results in increased abundance of NAD

NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209

G

aldo-keto reductase family 1 member A1

multiple interactions

NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1, member C1

multiple interactions

[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

multiple interactions

[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

multiple interactions

[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions
increases activity

[ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein]
NAD results in increased activity of ALDH1A1 protein

PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde

NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378

G

aldehyde dehydrogenase 2 family member

multiple interactions
affects binding
affects abundance

[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein]
ALDH2 protein binds to NAD
NAD binds to ALDH2 protein
Magnesium affects the reaction [NAD binds to ALDH2 protein]
ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD

PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 More...

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 3 family, member A1

multiple interactions
increases activity

[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde
NAD results in increased activity of ALDH3A1 protein

PMID:10856427 PMID:21256123

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

aldehyde dehydrogenase 5 family, member A1

multiple interactions

NAD binds to and affects the activity of ALDH5A1 protein

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

BCL2 associated X, apoptosis regulator

decreases expression

NAD results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression

NAD results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

3-hydroxybutyrate dehydrogenase 1

multiple interactions

NAD binds to and results in increased activity of BDH1 protein

NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671

G

3-hydroxybutyrate dehydrogenase 2

multiple interactions

NAD binds to and results in increased activity of BDH2 protein

NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072

G

basic helix-loop-helix ARNT like 1

decreases oxidation

BMAL1 gene mutant form results in decreased oxidation of NAD

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

caspase 3

multiple interactions

NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]

PMID:24040102 PMID:24491677

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 4

multiple interactions

NAD binds to and results in increased activity of CBR4 protein

NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cholinergic receptor nicotinic alpha 9 subunit

multiple interactions

CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192

G

colony stimulating factor 2

multiple interactions

[NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome b5 type B

multiple interactions

[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine

NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249

G

cytochrome b5 reductase 3

affects binding
multiple interactions

CYB5R3 protein binds to NAD
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine

PMID:16469290 PMID:25170804

NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298

G

dicarbonyl and L-xylulose reductase

multiple interactions

1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]

NCBI chr10:106,006,404...106,008,293

G

DEK proto-oncogene

increases oxidation

DEK protein results in increased oxidation of NAD

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

dehydrogenase/reductase 9

multiple interactions

NAD binds to and results in increased activity of DHRS9 protein

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

ecto-NOX disulfide-thiol exchanger 2

multiple interactions

[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD

NCBI chr X:128,270,941...128,593,074
Ensembl chr X:128,271,074...128,593,039

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions
decreases abundance
increases ADP-ribosylation
increases metabolic processing

ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
NAD results in increased ADP-ribosylation of ERCC6 protein
ERCC6 gene mutant form results in increased metabolism of NAD

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

UDP-galactose-4-epimerase

multiple interactions

NAD binds to and results in increased activity of GALE protein

NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388

G

polypeptide N-acetylgalactosaminyltransferase 1

increases expression

NAD results in increased expression of GALNT1 mRNA

NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

galactosidase, beta 1

multiple interactions

NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glycogen synthase kinase 3 beta

increases abundance
multiple interactions

GSK3B protein mutant form results in increased abundance of NAD metabolite
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]

PMID:25246272 PMID:25536389

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hydroxyacyl-CoA dehydrogenase

increases metabolic processing

HADH protein results in increased metabolism of NAD

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

[Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein

NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228

G

heparanase

increases expression

NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

HRas proto-oncogene, GTPase

multiple interactions

[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions

[Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxysteroid 11-beta dehydrogenase 2

increases reduction
multiple interactions

HSD11B2 protein results in increased reduction of NAD
Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

hydroxysteroid (17-beta) dehydrogenase 10

multiple interactions

[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein

NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488

G

hydroxysteroid (17-beta) dehydrogenase 11

multiple interactions

NAD binds to and results in increased activity of HSD17B11 protein

NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161

G

hydroxysteroid (17-beta) dehydrogenase 13

multiple interactions

NAD binds to and results in increased activity of HSD17B13 protein

NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166

G

hydroxysteroid (17-beta) dehydrogenase 14

multiple interactions

NAD binds to and results in increased activity of HSD17B14 protein

NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883

G

hydroxysteroid (17-beta) dehydrogenase 2

multiple interactions

NAD binds to and results in increased activity of HSD17B2 protein

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxysteroid (17-beta) dehydrogenase 4

multiple interactions

NAD binds to and results in increased activity of HSD17B4 protein

NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952

G

hydroxysteroid (17-beta) dehydrogenase 6

multiple interactions

NAD binds to and results in increased activity of HSD17B6 protein

NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425

G

hydroxysteroid (17-beta) dehydrogenase 8

multiple interactions

[Gossypol co-treated with NAD] binds to HSD17B8 protein

NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

NAD binds to and results in increased activity of HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

multiple interactions

NAD binds to and results in increased activity of HSD3B2 protein

NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7

multiple interactions

NAD binds to and results in increased activity of HSD3B7 protein

NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

insulin-like growth factor binding protein 1

multiple interactions
increases expression

NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
NAD results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 1 beta

multiple interactions

2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

insulin receptor

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

lactate dehydrogenase A

increases oxidation

LDHA protein results in increased oxidation of NAD

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

microRNA 34a

multiple interactions
decreases abundance

[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]

NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103

G

mitochondrial amidoxime reducing component 1

multiple interactions

[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine]

PMID:25170804 PMID:29856598

NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796

G

mitochondrial amidoxime reducing component 2

multiple interactions

[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine

NCBI chr13:96,362,810...96,397,284

G

mucin 2, oligomeric mucus/gel-forming

increases expression

NAD results in increased expression of MUC2 mRNA

NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756

G

NAD kinase

increases phosphorylation

NADK protein results in increased phosphorylation of NAD

NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322

G

NAD synthetase 1

multiple interactions

[NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD

NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869

G

nicotinamide phosphoribosyltransferase

increases chemical synthesis
multiple interactions

NAMPT protein results in increased chemical synthesis of NAD
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]

PMID:23834033 PMID:25505128

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

NADH:ubiquinone oxidoreductase subunit S4

affects abundance

NDUFS4 protein affects the abundance of NAD

NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846

G

NAD(P)H quinone dehydrogenase 1

increases oxidation
multiple interactions

NQO1 protein results in increased oxidation of NAD
NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

purinergic receptor P2Y1

multiple interactions

P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases abundance
affects abundance

[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]
PARP1 protein results in decreased abundance of NAD
5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD]
PARP1 protein mutant form affects the abundance of NAD
[2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
PARP1 protein affects the abundance of NAD

PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase family, member 10

decreases abundance

PARP10 protein results in decreased abundance of NAD

NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304

G

phospholipase A2 group VI

multiple interactions

PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

peroxisome proliferator-activated receptor gamma

decreases activity
multiple interactions

NAD results in decreased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

palmitoyl-protein thioesterase 1

affects abundance

PPT1 gene mutant form affects the abundance of NAD

NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048

G

retinol dehydrogenase 10

multiple interactions

NAD binds to and results in increased activity of RDH10 protein

NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572

G

retinol dehydrogenase 16

multiple interactions

NAD binds to and results in increased activity of RDH16 protein

NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124

G

retinol dehydrogenase 5

multiple interactions

NAD binds to and results in increased activity of RDH5 protein

NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558

G

short chain dehydrogenase/reductase family 16C, member 5

affects activity
multiple interactions

NAD affects the activity of SDR16C5 protein
NAD binds to and results in increased activity of SDR16C5 protein

PMID:18926804 PMID:25526675

NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970

G

short chain dehydrogenase/reductase family 9C, member 7

multiple interactions

NAD binds to and results in increased activity of SDR9C7 protein

NCBI chr 7:63,703,788...63,720,325
Ensembl chr 7:63,707,071...63,721,480

G

sirtuin 1

multiple interactions
increases response to substance
increases activity
decreases abundance

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
SIRT1 protein results in increased susceptibility to NAD
NAD results in increased activity of SIRT1 protein
[MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein
NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]

PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 More...

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sphingomyelin phosphodiesterase 2

affects activity

NAD affects the activity of SMPD2 protein

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441

G

sphingosine kinase 1

decreases activity

NAD results in decreased activity of SPHK1 protein

NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240

G

transaldolase 1

decreases abundance

TALDO1 gene mutant form results in decreased abundance of NAD

NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974

G

TDP-glucose 4,6-dehydratase

multiple interactions

NAD binds to and results in increased activity of TGDS protein

NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554

G

tumor protein p53

multiple interactions
decreases expression

[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein]
NAD results in decreased expression of TP53 protein

PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tyrosinase

multiple interactions
increases oxidation

ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]

NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207

G

UDP-glucuronate decarboxylase 1

multiple interactions

[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein

NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334

G

X-ray repair cross complementing 1

decreases reduction
multiple interactions

XRCC1 gene mutant form results in decreased reduction of NAD
[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]

PMID:30998386 PMID:35778544

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

NADP(+)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

acetylcholinesterase

multiple interactions

[Methyl Parathion co-treated with NADP] results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

allograft inflammatory factor 1

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein]

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

aldo-keto reductase family 1 member A1

multiple interactions

[AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]

PMID:15720144 PMID:21910479

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1 member B1

multiple interactions
affects binding
increases activity

[AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP binds to AKR1B1 protein binds to fidarestat
NADP results in increased activity of AKR1B1 protein

PMID:21910479 PMID:23295224 PMID:23295227

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

multiple interactions
increases activity
affects binding
decreases reduction

[AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
NADP results in increased activity of AKR1B10 protein
NADP binds to AKR1B10 protein mutant form binds to fidarestat
AKR1B10 protein results in decreased reduction of NADP

PMID:17329238 PMID:19013440 PMID:21910479 PMID:23295224 PMID:23295227

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldo-keto reductase family 1, member C1

multiple interactions

[AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]

PMID:21910479 PMID:23261716

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

multiple interactions

[AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]

PMID:14672942 PMID:21910479 PMID:23261716

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

multiple interactions

[AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]

PMID:14672942 PMID:21910479 PMID:23261716

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 1, member D1

multiple interactions

[AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldo-keto reductase family 7, member A2

multiple interactions

[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes

NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909

G

aldo-keto reductase family 7 member A3

multiple interactions

[AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

aldehyde dehydrogenase 2 family member

multiple interactions

1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 3 family, member A1

multiple interactions
increases activity

[ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde
NADP results in increased activity of ALDH3A1 protein

PMID:10856427 PMID:21256123

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

autophagy related 5

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

butyrylcholinesterase

multiple interactions

[diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein]

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

beclin 1

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

catalase

multiple interactions

CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 1

multiple interactions

[CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein

PMID:21910479 PMID:25526675 PMID:25541467

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

carbonyl reductase 3

multiple interactions

NADP binds to and results in increased activity of CBR3 protein

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

CD38 molecule

multiple interactions

CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

cathepsin B

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cytochrome b5 type A

multiple interactions

[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]

NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535

G

cytochrome b-245 beta chain

multiple interactions

CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein

PMID:15720144 PMID:24713513

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

PMID:7946932 PMID:11714871 PMID:20825217 PMID:24120545 PMID:33728909

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]

PMID:15720144 PMID:16120791 PMID:19463925

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily a, polypeptide 1

multiple interactions

[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily a, polypeptide 2

multiple interactions

[CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine

NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487

G

cytochrome P450, family 2, subfamily b, polypeptide 1

multiple interactions

[Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B1 protein

PMID:11805216 PMID:16485904

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]

PMID:11805216 PMID:16485904 PMID:25500267 PMID:32672941

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

PMID:16978661 PMID:21177487 PMID:24120545 PMID:36332690

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

multiple interactions

[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

G

cytochrome P450, family 2, subfamily d, polypeptide 2

multiple interactions

[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein]

NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

[CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

PMID:20825217 PMID:24120545 PMID:32198085

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein

PMID:11181492 PMID:24713513

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions

NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein]

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

PMID:16153789 PMID:19818743 PMID:20825217 PMID:21766881 PMID:22390216 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

[CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 62

multiple interactions

[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP3A62 protein

NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833

G

dicarbonyl and L-xylulose reductase

multiple interactions

[2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]

PMID:21910479 PMID:25526675 PMID:28595002

NCBI chr10:106,006,404...106,008,293

G

2,4-dienoyl-CoA reductase 1

multiple interactions

NADP binds to and results in increased activity of DECR1 protein

NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018

G

2,4-dienoyl-CoA reductase 2

multiple interactions

NADP binds to and results in increased activity of DECR2 protein

NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479

G

dihydrofolate reductase

decreases activity

NADP analog results in decreased activity of DHFR protein

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 1

multiple interactions

NADP binds to and results in increased activity of DHRS1 protein

NCBI chr15:29,236,522...29,243,807
Ensembl chr15:29,236,522...29,243,838

G

dehydrogenase/reductase 11

multiple interactions

NADP binds to and results in increased activity of DHRS11 protein

NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295

G

dehydrogenase/reductase 13

multiple interactions

NADP binds to and results in increased activity of DHRS13 protein

NCBI chr10:62,920,791...62,925,952

G

dehydrogenase/reductase 2

multiple interactions

[NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein

PMID:16685466 PMID:25526675

NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644

G

dehydrogenase/reductase 3

multiple interactions
increases activity

NADP binds to and results in increased activity of DHRS3 protein
NADP results in increased activity of DHRS3 protein

PMID:25451588 PMID:25526675

NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417

G

dehydrogenase/reductase 4

multiple interactions

NADP binds to and results in increased activity of DHRS4 protein

NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127

G

dehydrogenase/reductase 7

multiple interactions

NADP binds to and results in increased activity of DHRS7 protein

NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892

G

dehydrogenase/reductase 7B

multiple interactions

NADP binds to and results in increased activity of DHRS7B protein

NCBI chr10:45,504,344...45,537,094
Ensembl chr10:45,504,426...45,537,076

G

dehydrogenase/reductase 7C

multiple interactions

NADP binds to and results in increased activity of DHRS7C protein

NCBI chr10:52,495,262...52,513,338
Ensembl chr10:52,495,262...52,513,338

G

fatty acyl CoA reductase 1

multiple interactions

NADP binds to and results in increased activity of FAR1 protein

NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730

G

fatty acyl CoA reductase 2

multiple interactions

NADP binds to and results in increased activity of FAR2 protein

NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255

G

Fas ligand

multiple interactions

CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

multiple interactions

NADP binds to and results in increased activity of FASN protein

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

glucose-6-phosphate dehydrogenase

increases reduction
increases expression

G6PD protein results in increased reduction of NADP
NADP results in increased expression of G6PD protein

PMID:1922005 PMID:5432368

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

glial fibrillary acidic protein

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

GDP-L-fucose synthase

multiple interactions

NADP binds to and results in increased activity of GFUS protein

NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948

G

glutamate dehydrogenase 1

multiple interactions

[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

GDP-mannose 4, 6-dehydratase

multiple interactions

NADP binds to and results in increased activity of GMDS protein

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961

G

glycogen synthase kinase 3 beta

increases abundance

GSK3B protein mutant form results in increased abundance of NADP metabolite

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions
increases oxidation

NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein]
GSR protein results in increased oxidation of NADP
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]
Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]

PMID:17937621 PMID:19167472 PMID:19668867 PMID:22036979 PMID:24634002

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
increases reduction
increases oxidation

NADP binds to and results in increased activity of HSD11B1 protein
HSD11B1 protein results in increased reduction of NADP
Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]

PMID:25526675 PMID:26859423

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

NADP binds to and results in increased activity of HSD11B2 protein

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein

PMID:21232530 PMID:25526675

NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927

G

hydroxysteroid (17-beta) dehydrogenase 12

multiple interactions

NADP binds to and results in increased activity of HSD17B12 protein

NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions

NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein

PMID:20522127 PMID:25526675

NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554

G

hydroxysteroid (17-beta) dehydrogenase 7

multiple interactions

NADP binds to and results in increased activity of HSD17B7 protein

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

hydroxysteroid (17-beta) dehydrogenase 8

multiple interactions

NADP binds to and results in increased activity of HSD17B8 protein

NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

[Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

hydroxysteroid dehydrogenase like 1

multiple interactions

NADP binds to and results in increased activity of HSDL1 protein

NCBI chr19:47,615,794...47,631,892
Ensembl chr19:47,615,796...47,631,846

G

hydroxysteroid dehydrogenase like 2

multiple interactions

[22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

HIV-1 Tat interactive protein 2

multiple interactions

NADP binds to and results in increased activity of HTATIP2 protein

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of NADP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

insulin 1

multiple interactions

[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

iodotyrosine deiodinase

increases oxidation

IYD protein results in increased oxidation of NADP

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

affects binding
multiple interactions

NADP binds to KCNAB2 protein
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite

PMID:19013139 PMID:21296056

NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243

G

3-ketodihydrosphingosine reductase

multiple interactions

NADP binds to and results in increased activity of KDSR protein

NCBI chr13:22,862,117...22,894,118
Ensembl chr13:22,862,117...22,894,108

G

Kelch-like ECH-associated protein 1

affects abundance

KEAP1 protein affects the abundance of NADP

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

lysosomal-associated membrane protein 1

multiple interactions

NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

methionine adenosyltransferase 2 non-catalytic beta subunit

multiple interactions

[resveratrol co-treated with NADP] binds to MAT2B protein; NADP binds to and results in increased activity of MAT2B protein

NCBI chr10:25,106,928...25,122,982
Ensembl chr10:25,106,930...25,122,777

G

NAD kinase

multiple interactions

[3-(1-deoxyribofuranosyl)benzamide results in decreased activity of NADK protein] which results in decreased abundance of NADP

NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322

G

N-acetyltransferase 1

multiple interactions

[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone

NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520

G

N-acetyltransferase 2

multiple interactions

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

NFE2 like bZIP transcription factor 2

affects abundance
affects oxidation

NFE2L2 protein affects the abundance of NADP
NFE2L2 protein affects the oxidation of NADP

PMID:21775727 PMID:29950142

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NmrA like redox sensor 1

multiple interactions

[Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein

NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes
NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]

PMID:20545351 PMID:21910479 PMID:27558805

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

NAD(P) dependent steroid dehydrogenase-like

multiple interactions

NADP binds to and results in increased activity of NSDHL protein

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

poly (ADP-ribose) polymerase 1

multiple interactions

[3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

peroxisomal trans-2-enoyl-CoA reductase

multiple interactions

[Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein

NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511

G

phosphogluconate dehydrogenase

increases expression

NADP results in increased expression of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

cytochrome p450 oxidoreductase

multiple interactions
increases metabolic processing

NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP
diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]
[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]

PMID:18206659 PMID:20545351 PMID:20561902 PMID:21215309 PMID:22390216 More...

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peptidylprolyl isomerase F

multiple interactions

[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]

NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913

G

prion protein

multiple interactions

[NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein]
[Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]

PMID:16990274 PMID:19149680

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

prostaglandin reductase 1

multiple interactions

[PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene

PMID:11524419 PMID:21939268

NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666

G

quinoid dihydropteridine reductase

multiple interactions

NADP binds to and results in increased activity of QDPR protein

NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854

G

retinol dehydrogenase 11

multiple interactions

NADP binds to and results in increased activity of RDH11 protein

NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252

G

retinol dehydrogenase 12

multiple interactions

NADP binds to and results in increased activity of RDH12 protein

NCBI chr 6:98,015,465...98,028,388
Ensembl chr 6:98,015,465...98,028,388

G

retinol dehydrogenase 13

multiple interactions

NADP binds to and results in increased activity of RDH13 protein

NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908

G

retinol dehydrogenase 14

multiple interactions

NADP binds to and results in increased activity of RDH14 protein

NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712

G

retinol dehydrogenase 8

multiple interactions

NADP binds to and results in increased activity of RDH8 protein

NCBI chr 8:19,353,191...19,360,462
Ensembl chr 8:19,353,191...19,360,462

G

short chain dehydrogenase/reductase family 39U, member 1

multiple interactions

NADP binds to and results in increased activity of SDR39U1 protein

NCBI chr15:29,378,156...29,380,989
Ensembl chr15:29,378,026...29,381,560

G

short chain dehydrogenase/reductase family 42E, member 1

multiple interactions

NADP binds to and results in increased activity of SDR42E1 protein

NCBI chr19:45,715,366...45,727,901
Ensembl chr19:45,715,399...45,727,901

G

sepiapterin reductase

multiple interactions

NADP binds to and results in increased activity of SPR protein

NCBI chr 4:117,671,948...117,676,292
Ensembl chr 4:117,671,949...117,675,678

G

sequestosome 1

multiple interactions

NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sulfotransferase family 1A member 1

multiple interactions

[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

transaldolase 1

decreases abundance
multiple interactions

TALDO1 gene mutant form results in decreased abundance of NADP
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]

NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974

G

tryptophan 2,3-dioxygenase

affects abundance

TDO2 protein affects the abundance of NADP

NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511

G

TP53 induced glycolysis regulatory phosphatase

multiple interactions
increases abundance

NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein]
TIGAR protein results in increased abundance of NADP
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]

PMID:32057834 PMID:33359019

NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029

G

tumor protein p53

multiple interactions

NADP promotes the reaction [sodium bichromate results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

multiple interactions

[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

multiple interactions
increases reduction

[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein]
NADP results in increased reduction of TXNRD1 protein
[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]

PMID:17640917 PMID:17937621 PMID:20457604 PMID:20810785 PMID:22694104 More...

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

WW domain-containing oxidoreductase

multiple interactions

NADP binds to and results in increased activity of WWOX protein

NCBI chr19:42,432,141...43,360,278
Ensembl chr19:42,432,152...43,359,391

nicotinic acid-adenine dinucleotide phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CD38 molecule

multiple interactions

CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

endothelin 1

increases metabolic processing
multiple interactions

EDN1 protein results in increased metabolism of NAADP
NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

Fas ligand

multiple interactions
increases abundance

CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

mucolipin TRP cation channel 1

increases activity
multiple interactions

NAADP results in increased activity of MCOLN1 protein
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium

NCBI chr12:1,560,341...1,574,252
Ensembl chr12:1,560,359...1,574,252

G

NADPH oxidase 1

multiple interactions

NOX1 mutant form inhibits the reaction [EDN1 protein results in increased metabolism of NAADP]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19844
role	19820
biological role	19818
biochemical role	19525
cofactor	16179
coenzyme	1016
NAD(P)	190
NAD(P)(+)	190
NAD(+)	89
NADP(+) +	122
Path 2
Term	Annotations
CHEBI ontology	19844
subatomic particle	19842
composite particle	19842
hadron	19842
baryon	19842
nucleon	19809
atomic nucleus	19842
atom	19842
main group element atom	19792
p-block element atom	19792
chalcogen	19548
oxygen atom	19491
oxygen molecular entity	19523
hydroxides	19331
oxoacid	18762
pnictogen oxoacid	14895
phosphorus oxoacid	14485
phosphoric acids	11416
phosphoric acid	13924
phosphoric acid derivative	13830
phosphate	13829
organic phosphate	13829
nucleoside phosphate	1856
nucleotide	1853
pyridine nucleotide	229
nicotinamide nucleotide	229
nicotinamide dinucleotide	190
NAD(P)	190
NAD(P)(+)	190
NAD(+)	89
NADP(+) +	122

paths to the root